Genera Research Ltd.

Genera Research – Regrowing bone with the patient's own blood

OSTEOGROW platform

OSTEOGROW turns a patient's own blood into new bone. A small dose of recombinant human bone morphogenetic protein 6 (rhBMP6) is mixed with the patient's blood in the operating room, forming a natural clot that releases the bone-forming signal exactly where it is needed. No animal-derived collagen, no donor tissue, and no second surgery to harvest the patient's own bone. Completed clinical trials have treated more than 250 patients. In those trials, no treatment-related serious adverse events occurred, and no patient developed antibodies against rhBMP6. One platform is being developed for three indications: nonunion fractures, spinal fusion, and dental bone regeneration.

Genera Research is a Croatian clinical-stage biopharmaceutical company, founded in 2001 near Zagreb. We are developing OSTEOGROW, a new treatment for bone regeneration. It combines our recombinant human bone morphogenetic protein 6 (rhBMP6, INN bezeotermin alfa) with an autologous blood coagulum made from the patient's own blood. Because it uses no animal-derived or synthetic carriers, OSTEOGROW works with the body's natural healing process to form new bone where it has failed to form on its own.

What makes us special

• Clinically validated: five completed Phase I/II trials in more than 300 patients, with no adverse events reported
• Fully in-house: our own rhBMP6 production process and a growing GMP/QMS infrastructure
• Strong IP: global patent protection through 2043
• Recognized by the EU: about €19M in non-dilutive EU funding and an EIC Accelerator Blended Finance award

Our goals

We are moving OSTEOGROW into Phase III for fracture non-union (OSTEOforUNION), alongside programs in spinal fusion and dental bone augmentation. We want to give patients and surgeons an effective biological alternative to bone grafting and repeat surgery.

Our challenge

We are raising a Series A round and looking for a lead investor to match the €5.8M EIC equity commitment. The EIC's 1:1 matching gives new investors strong capital efficiency. We are also open to strategic partners in orthopedics, spine, and dental, as well as licensing and distribution partners in key markets.

Our vision

We want to make OSTEOGROW the standard of care for difficult bone healing worldwide: a safer, simpler and more natural way to restore mobility and quality of life.

Meet us at the EIC Pavilion, MEDICA 2026, Düsseldorf, 16–19 November.